share_log

Cantor Fitzgerald Initiates Coverage On Verve Therapeutics With Neutral Rating, Announces Price Target of $21

Cantor Fitzgerald Initiates Coverage On Verve Therapeutics With Neutral Rating, Announces Price Target of $21

坎托·菲茨杰拉德以中性评级开始对Verve Therapeutics进行报道,宣布目标股价为21美元
Benzinga Real-time News ·  2023/02/01 07:57

Cantor Fitzgerald analyst Rick Bienkowski initiates coverage on Verve Therapeutics (NASDAQ:VERV) with a Neutral rating and announces Price Target of $21.

Cantor Fitzgerald分析师Rick Bienkowski以中性评级启动对Verve治疗公司(纳斯达克:VERV)的报道,并宣布目标价为21美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发